Filing Flows › Celldex Therapeutics (CLDX) › Q4 2024
Celldex Therapeutics (CLDX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Celldex Therapeutics (CLDX) reported revenue of $1.2M for the fourth quarter 2024 (Q4 2024), -72% from a year earlier and -63% from the quarter before.
Celldex Therapeutics, Q4 2024: revenue $1.2M (-72% year over year), net loss $47.1M, operating cash flow −$32.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -63% | -72% |
| Operating profit | −$56.0M | — | — |
| Net earnings | −$47.1M | — | — |
| Operating cash flow | −$32.5M | — | — |
What changed
Revenue was $1.2M in Q4 2024, down 72% year over year and down 63% from the previous quarter. Contracts and grants was the largest line at 99% of revenue.
Operating costs exceeded revenue by $56.0M, an operating margin of -4768.3%. Total costs grew 11% against a revenue fall of 72%. The fastest-growing cost line was Research & development (+54%). The quarter ended with a net loss of $47.1M, wider than the previous quarter's $42.1M loss.
Operating cash flow was −$32.5M. Non-cash charges added back $819K of depreciation and amortization and $9.8M of share-based compensation. Working capital and other items added $4.0M. Capital expenditures of $756K exceeded it, leaving free cash flow of −$33.2M.
Questions
What was Celldex Therapeutics' revenue in the fourth quarter 2024?
Celldex Therapeutics (CLDX) reported revenue of $1.2M for the fourth quarter 2024 (Q4 2024), -72% from a year earlier and -63% from the quarter before.